Siga Technologies (SIGA) Other financing activities (2017 - 2018)
Siga Technologies (SIGA) posted Other financing activities of $9200.0 for Q4 2018, down 96.36% on a QoQ basis from $252679.0 in Q3 2018, and down 85.16% year-over-year from $62001.0 in Q4 2017.
Siga Technologies (SIGA) Other financing activities (2017 - 2018) Analysis & Trends
Siga Technologies' Other financing activities history runs 2 years deep, the most recent figure standing at $9200.0 for Q4 2018.
- Quarterly Other financing activities fell 85.16% year-over-year to $9200.0 in Q4 2018, while the trailing twelve-month figure through Dec 2019 was $323880.0 (changed 0.0% YoY) and the FY2018 annual result came in at $261879.0, up 192.61% from the prior year.
- Other financing activities was $9200.0 for Q4 2018 at Siga Technologies, down from $252679.0 in the prior quarter.
- Across five years, Other financing activities topped out at $252679.0 in Q3 2018 and bottomed at $9200.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Siga Technologies | 225.56 Mn | 70.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 9,200.00 |
| Dec 31, 2018 | 9,200.00 |
| Sep 30, 2018 | 252,679.00 |
| Sep 30, 2018 | 252,679.00 |
| Dec 31, 2017 | 62,001.00 |
| Dec 31, 2017 | 62,001.00 |